Every letter we have printed

Your point about the 280 nm wavelength is the most useful thing I have read this year. I checked the four certificates in my drawer and two of them read at 280.

Attributing an outcome to one arm of a multi-receptor compound is not possible from the clinical data alone. The attribution comes from preclinical work with selective tools, and it should be labelled as such wherever it appears.

Where two activities act on the same downstream endpoint, additivity cannot be assumed and is rarely tested. The interaction term is the interesting quantity and almost no study is designed to estimate it.

The half-life to steady-state arithmetic deserves to be spelled out every time, because it is the single most useful calculation in this subject. Four to five half-lives to approach steady state means a weekly molecule with a week-long half-life takes over a month, and every dose-response impression formed before then is formed on incomplete exposure.

Time to steady state is determined by the elimination half-life and nothing else, and it differs between the compounds under discussion by enough to matter for how any schedule behaves in its first weeks.

Recording the site alongside the date turns a habit into data, and anybody keeping such a record for six months will learn more about their own pattern than any general advice can tell them.

A simple scheme beats a complicated one because it gets followed. Dividing the available area into quadrants and moving on a fixed rotation is enough, and elaborate maps do not survive contact with a busy week.

What is missing from the evidence base is any comparison of holding strategies. We have trials of schedules and no trials of the discretion applied to them, so every statement about how long to hold is extrapolation. Saying so plainly would be an improvement on most of what is written.

Tolerability-led escalation is the practice your article describes most sympathetically and it is worth naming what it gives up. Holding a dose because of symptoms is reasonable; holding it indefinitely because a schedule was never revisited is drift, and the two look identical from the outside.

A small thing. You give the semaglutide diabetes ladder as ending at 2.0 mg and the weight ladder at 2.4 mg, without explaining why the same molecule has two ceilings for two indications. It looks arbitrary and I suspect it is not.

Custody protects the supplier at least as much as the buyer. A result produced from a sample of unknown history is not evidence against anybody, and suppliers who understand that ought to be the loudest advocates for the practice.

Sealed does not mean unopened. A crimp seal can be lifted and replaced by anybody with the right tool, and the visual check most buyers perform would not detect it. Tamper-evident and sealed are different properties sold under one word.

A badge is a statement about a moment. It says a sample submitted on a particular day met a particular threshold, and it is displayed indefinitely on a page selling material made months later. Nothing dishonest has happened and the reader has still been told something untrue.

Nobody expires anything. A badge granted three years ago is still on the page, still linking to a report about a lot that ran out long ago, and there is no mechanism anywhere in the chain that removes it. Decay is the missing feature.

The precision of the instrument, the magnitude of the reported change and the duration of the study should always be given together. Any two of the three without the third leaves the reader unable to judge whether anything was measured at all.

Mass loss of any origin is associated with density change in the older literature, which makes the untreated comparator essential and frequently absent. Without it the question of attribution cannot be approached at all.

Strength can be maintained while cross-sectional area falls, because a good deal of early strength change is neural. Readers using performance as a proxy for tissue are using a proxy that moves for other reasons, in both directions.

An activity component in a trial is also an attention component, and the two cannot be separated in an unblinded design. Some part of any benefit attributed to training is attributable to contact with the study team.

The pieces I have found most useful are the ones that concluded nothing very much. Reporting the absence of a finding is a service and it does not read as one at first.

Constipation and diarrhoea both appear in the same tables and they are not the same phenomenon at all. Grouping them as gastrointestinal events obscures that motility is affected in more than one place and in more than one direction.

What is missing from the mechanistic literature is anything about the microbiome, which is either an enormous omission or a sensible refusal to speculate. I have not been able to decide which, and neither, apparently, has anybody else.

Meal size and composition adjustments are the interventions with the most consistent anecdotal support and the least formal study. That combination is worth naming, because it tells a reader how much confidence to place in advice that everyone repeats.

Your incidence tables are from the licensed products. I use compounded material at a concentration that does not match any pen. Are the figures transferable at all?

Please continue to state plainly what has not been established. It is the part of your reporting I have come to rely on most.

There is a category I would call loss of a reason to continue: the original motivation resolved, changed or receded. It is neither efficacy nor tolerability nor cost, and it may be the most common cause of a long arrangement ending quietly.

The word discontinuation implies an endpoint that has been reached. A great many of the accounts I read describe an intention to resume that was never acted on, which is a different phenomenon recorded under the same heading.

Where two activities produce the same effect by different routes, the combined result may be less than the sum, and that is the direction the pharmacology usually predicts. Popular accounts assume the other direction without argument.

A caution on cross-molecule potency comparisons. Milligram-for-milligram statements between agents with different receptor profiles and different half-lives are close to meaningless, and they are the commonest error I see in general coverage. Your department avoids them, which is why I read it.

Transaminases falling as hepatic fat falls is one of the more consistent findings in this area, and it is worth stating that the direction is downwards, because readers primed to expect harm will read any liver panel with alarm.

Estimating equations for renal function were derived in specific populations and include terms for body size that behave oddly during a period of change. The estimate can move while the underlying measurement does not.

A reference interval is a description of a population, not a definition of health, and your piece is one of the few places I have seen that said so plainly. Ninety-five per cent coverage means one person in twenty who is entirely well will fall outside it on any given analyte, before anything at all has happened to them.

Intervals differ between laboratories because the assays differ, and results from two laboratories cannot be compared without the intervals beside them. People compare them constantly and the difference is attributed to their own biology.

Trifluoroacetate in the mobile phase is the practical villain. It pairs with basic residues, suppresses signal badly in the negative mode and moderately in the positive, and it is present because the chromatographer needed peak shape. The two halves of the experiment are working against each other and nobody owns the conflict.

Your account of electrospray is clear but it understates how much the additive matters. A mobile phase carrying trifluoroacetic acid suppresses ionisation substantially, which is why a laboratory running an excellent chromatographic method sometimes has to change it entirely before the same sample will give a usable spectrum. The two techniques want different solvents.

You state that fourteen of twenty suppliers report an MS identity test. Does that count reports supplied to you on request, or only what appears on the certificate a customer receives?

In defence of the retention-time comparison your article is rude about: run against a properly characterised standard on a stated method, co-elution plus a matching mass is genuinely strong evidence. The weakness is not the logic, it is that the standard is usually a previous lot of the same product.

Sixteen years in a peptide plant and I have never once been asked by a customer which ionisation source we used. I have been asked hundreds of times for a purity figure to one more decimal place.

Trace metals catalyse oxidation at concentrations far below anything a specification would flag. It is a plausible explanation for lot-to-lot variation that has nothing to do with the synthesis and everything to do with the water.

Oxidation of methionine is fast, common and detectable, and the mass shift is small enough that a low-resolution instrument will miss it. It is a good example of a pathway that is easy to find if you look for it and easy to miss otherwise.

Repeated puncture of a stopper is a sterility question and a stability one. Each entry admits a small volume of air, and oxidation-sensitive residues care about that whether or not anything grows.